New York, May 28, 2026, 06:04 EDT
- Maze was indicated at $26.05, down roughly 1.2% in early Nasdaq quotes before the session opened.
- The company said CEO Jason Coloma is set to appear at the Jefferies and Goldman Sachs healthcare conferences in June.
- Maze’s MZE829 drug for kidney disease is drawing investor attention. They’re watching the route to a bigger pivotal trial.
Maze Therapeutics stock was little changed in Thursday’s premarket trade as investors shrugged off a sparse update from the company. Focus is already shifting to June, when investor events could provide more detail on Maze’s main kidney-disease program.
The stock fell about 1.2% to $26.05 in recent trade, leaving the South San Francisco biotech’s market value near $1.4 billion. Biotech shares elsewhere traded higher. The SPDR S&P Biotech ETF was up 0.8%. The iShares Nasdaq Biotechnology ETF added 0.3%.
Maze is in a key spot between releasing data and getting things done. Nasdaq’s pre-market opens ahead of the regular 9:30 a.m. Eastern start, and the company’s new update puts the chief executive in front of investors twice before mid-June.
Maze said late Wednesday that CEO Jason Coloma will be on stage at the Jefferies Global Healthcare Conference in New York on June 3, then at the Goldman Sachs Global Healthcare Conference on June 10. Both appearances will be webcast live, with replays online for 60 days.
Maze’s next appearances are expected to face questions about MZE829, the company’s oral APOL1 inhibitor for APOL1-mediated kidney disease, a genetic kidney damage disorder. APOL1 is a gene tied to raised kidney-disease risk. Proteinuria, the main measure in Maze’s trial, shows protein leaking into urine and signals kidney injury.
Maze said earlier this month it ended up with $528 million in cash, cash equivalents and marketable securities after April’s stock sale and a milestone from Shionogi, which should cover operations into 2029. CEO Jason Coloma said he’s “more confident than ever” following positive Phase 2 HORIZON results, and the company still expects to start a Phase 2 MZE782 study in phenylketonuria around mid-year. Maze Therapeutics
The main stock question isn’t about cash. The issue investors are watching is whether MZE829 will advance straight from its Phase 2 trial to a pivotal study, the larger trial needed for a regulatory nod.
Maze said in March that MZE829 lowered proteinuria by 35.6% on average at week 12 among broad AMKD patients, and by 61.8% in a small focal segmental glomerulosclerosis group. That’s a severe kidney-scarring disease. Chief Medical Officer Harold Bernstein called the data “initial promising proof-of-concept” and said Maze would talk to regulators and advisers about the pivotal program. Maze Therapeutics
Wall Street analysts are reading Maze’s latest move differently. BioPharma Dive quoted Mizuho Securities’ Salim Syed saying the drug looks “best-in-class” for broad AMKD and is “likely approvable.” But Leerink Partners’ Joseph Schwartz told the site it’s “apples to oranges” to compare Maze’s drug with Vertex’s inaxaplin, and pointed to the stock drop as a “vast overreaction.” BioPharma Dive
Vertex stands out as the main peer here. Fierce Biotech said Vertex’s inaxaplin study cut protein in urine by about 43% in 13 FSGS patients, while Maze’s MZE829 showed an average 62% drop in four patients with similar disease. Vertex is working on a larger Phase 2/3 trial with results due later this year. Maze CEO Coloma told investors in March that diabetes data “definitely moves the field forward.” Fierce Biotech
The risk hasn’t gone away. MZE829’s best data showed up in small subgroups, with less clarity in diabetics. BioSpace cited Truist analysts pointing to a sample size that “limits interpretation.” Mizuho said investors were “getting hung up” on the wider population. BioSpace
Maze’s stock is still backed by a few analysts, but there’s little space for unclear messaging. The June conferences aren’t set up for clinical data. For Maze, where a lot of the current value relies on trial setup, regulator comments and the coming HORIZON readout, even slight tone shifts could be important.
